Review highlights IBD management strategies during pregnancy, emphasizing medication safety for maternal health and fetal outcomes.
Inflammatory bowel disease (IBD) can impact reproductive planning. Achieving disease remission prior to conception is advised, as it can reduce risks for both the mother and the infant. Flare-ups during pregnancy can lead to complications, such as preterm birth. Therefore, managing the disease effectively with the right medications is crucial for optimal outcomes. Most IBD medications (except small molecules and methotrexate) carry minimal risks to the fetus and are safe during breastfeeding, so it is important for individuals to understand the potential dangers of discontinuing treatment and the significance of maintaining remission. Given the rapid change in medical therapies, this review highlights the latest evidence to ensure successful pregnancy outcomes.
No takes yet. Share an insight, caveat, or question.
Cates et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: